New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
08:50 EDTLMNX, LHLabCorp announces availability of xTAG CYP2D6 genotype assay
LabCorp (LH) announced the availability of the xTAG CYP2D6 Kit v3 from Luminex (LMNX). The xTAG CYP2D6 Kit v3 is an FDA cleared qualitative genotyping assay that aids clinicians in determining strategies for therapeutics metabolized by the CYP2D6 gene product.
News For LH;LMNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 28, 2015
08:04 EDTLHLabCorp results show lab trends improving, says Baird
Subscribe for More Information
April 27, 2015
16:10 EDTLMNXLuminex updates clinical trial for the ARIES HSV 1&2 Assay
Subscribe for More Information
10:03 EDTLHLabCorp says diagnostics business will continue to drive top line
Subscribe for More Information
09:43 EDTLHLabCorp says sees continued improvement in Covance
Subscribe for More Information
06:50 EDTLHLabCorp reports Q1 LabCorp Diagnostics up 4.9% to $1.48B
Subscribe for More Information
06:49 EDTLHLabCorp: Q1 earnings reduced by restructuring and special items of $191.3M
As a result, the company recognized net earnings in the quarter of $700K, or 1c per diluted share, compared to $113.1 million, or $1.31 per diluted share, last year.
06:48 EDTLHLabCorp raises FY15 adjusted EPS to $7.55-$7.90 from $7.35-$7.70
Subscribe for More Information
06:45 EDTLHLabCorp reports Q1 adjusted EPS $1.73, consensus $1.63
Subscribe for More Information
April 21, 2015
08:14 EDTLHQuest Diagnostics and Inserm launch BRCA Share initiative
Quest Diagnostics (DGX) and Inserm, the French National Institute of Health and Medical Research institution, launched BRCA Share, a novel datashare initiative they co-founded to provide scientists and laboratory organizations around the world with open access to BRCA1 and BRCA2 genetic data. The program's goal is to accelerate research on BRCA gene mutations, particularly variants of uncertain significance, to improve the ability of clinical laboratory diagnostics to predict which individuals are at risk of developing hereditary breast and ovarian cancers. Laboratory Corporation of America Holdings (LH) is the first participant in the initiative, which is structured as a user group. B
06:40 EDTLHStart-up to offer saliva test for breast cancer susceptibility, NY Times says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use